Oncternal Therapeutics, Inc.

ONCT

US68236P2065

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-20 pm EDT			5-day change	1st Jan Change
8.6 ^USD	-0.69%		0.00%	-19.81%

May. 09	Transcript : Oncternal Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09	Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Oncternal Therapeutics, Inc. Elects Jinzhu Chen as Class II Director

May 28, 2021 at 05:04 pm EDT

Oncternal Therapeutics, Inc. announced that at its AGM held on May 25, 2021, it elected Jinzhu Chen as Class II director for a three-year term to expire at the 2024 annual meeting of stockholders.

Latest news about Oncternal Therapeutics, Inc.

Transcript : Oncternal Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 09	CI
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	Apr. 18	CI
HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating	Apr. 15	MT
Transcript : Oncternal Therapeutics, Inc. - Special Call	Mar. 19
Transcript : Oncternal Therapeutics, Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Oncternal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science	Feb. 01	CI
Oncternal Therapeutics, Inc. Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	Jan. 08	CI
Traders Look Ahead to Flat Day After Post-Christmas Rally	Dec. 27	MT
Top Premarket Decliners	Dec. 27	MT
Sector Update: Health Care Stocks Stronger Late Afternoon	Dec. 26	MT
Sector Update: Health Care Stocks Steady Tuesday Afternoon	Dec. 26	MT
Oncternal Therapeutics Says One Patient Dies in Dose Expansion Phase 1/2 Trial of ONCT-808 for B-cell Lymphoma; Shares Fall	Dec. 26	MT
Oncternal Therapeutics, Inc. Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma	Dec. 26	CI
North American Morning Briefing : China Outlook -2-	Dec. 05	DJ
Brookline Capital Upgrades Oncternal Therapeutics to Buy From Hold, Price Target is $2	Dec. 04	MT
Transcript : Oncternal Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Oncternal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Oncternal Therapeutics Gets FDA Fast-Track on Prostate Cancer Treatment	23-10-26	DJ
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer	23-10-26	CI
Oncternal Therapeutics, Inc. Adds Matthew Smith to its Prostate Cancer Scientific Advisory Board	23-10-25	CI
Oncternal Therapeutics Doses First Patient in Study of Prostate Cancer Drug	23-10-05	MT
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer	23-10-05	CI

Chart Oncternal Therapeutics, Inc.

Duration

Period

More charts

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Companyâs product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.

Sector

Biotechnology & Medical Research

Calendar

2024-06-20 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Oncternal Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.6 USD

Average target price

30.67 USD

Spread / Average Target

+256.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ONCTERNAL THERAPEUTICS, INC.	-19.81%	25.45M
MODERNA, INC.	+41.79%	54.04B
IQVIA HOLDINGS INC.	-0.56%	41.92B
LONZA GROUP AG	+48.83%	41.96B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B

Other Biotechnology & Medical Research